Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | M1774 |
Synonyms | |
Therapy Description |
M1774 is an ATR inhibitor, which potentially decreases tumor growth (Cancer Res (2022) 82 (12_Supplement): 2588). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M1774 | M-1774|M 1774|tuvusertib | ATR Inhibitor 16 | M1774 is an ATR inhibitor, which potentially decreases tumor growth (Cancer Res (2022) 82 (12_Supplement): 2588). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATRX inact mut | ovarian cancer | predicted - sensitive | M1774 | Case Reports/Case Series | Actionable | In a Phase I trial (DDRiver Solid Tumours 301), a patient with ovarian cancer harboring an inactivating mutation in ATRX experienced a partial response on treatment with M1774 (Ann Oncol (2022) 33 (suppl_7): S747-S748; NCT04170153). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05947500 | Phase II | M1774 Avelumab + M1774 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | Recruiting | USA | 0 |
NCT05828082 | Phase II | M1774 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | Recruiting | USA | 0 |
NCT05396833 | Phase I | M1774 | Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) | Recruiting | USA | ESP | CAN | 0 |
NCT04170153 | Phase I | M1774 | M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors | Active, not recruiting | USA | GBR | ESP | 2 |